Clinically Meaningful Change Estimates for the National Eye Institute Visual Function Questionnaire-25 in Patients With Diabetic Macular Edema
Translational Vision Science & Technology · 2024
DOI: 10.1167/tvst.13.12.27 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Translational Vision Science & Technology, 2024. Verfasst von Neil Bressler und 3 weiteren Autor:innen. Beteiligte Einrichtung: Wilmer Eye Institute, The Johns Hopkins University School of Medicine, Baltimore, MD, USA. Hauptthemen laut MEDLINE: Macular Edema, Diabetic Retinopathy, Visual Acuity, Ranibizumab. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Purpose
To derive estimates of clinically meaningful change (improvement) on the 25-item National Eye Institute Visual Function Questionnaire (NEI VFQ-25) in patients with diabetic macular edema (DME) using anchor- and distribution-based methods.
Methods
In this exploratory post hoc analysis of data from the RIDE/RISE (NCT00473382/NCT00473330) clinical trials of ranibizumab for DME, the NEI VFQ-25 was completed at baseline and six, 12, 18, and 24 months. Anchor-based (≥5-, ≥10-, and ≥15-letter gain in best-corrected visual acuity [BCVA]) and distribution-based estimates were calculated. Subgroup analyses included outcomes when the study eye was the better- or worse-seeing eye.
Results
Baseline characteristics were balanced between the trials (RIDE, N = 382; RISE, N = 377). Anchor-based estimates of clinically meaningful improvement in composite scores (for ≥15-letter gain in BCVA) were 3.78 and 2.23 for RIDE and RISE, respectively. Estimates appeared similar for most subscales: near activities (4.11 and 3.31), distance activities (3.53 and 3.74), driving difficulties (5.15 and 3.15), and vision-specific dependency (4.70 and 1.83). Supportive distribution-based meaningful change composite score estimates also were similar between RIDE and RISE for values based on 0.5 standard deviation (9.85 and 9.70, respectively) or standard error of the mean (5.10 and 4.82, respectively).
Conclusions
These analyses suggest improvement of three to five points on the NEI VFQ-25 composite score and four individual subscales as clinically meaningful in patients with DME. Translational Relevance: This analysis supports considering these thresholds when assessing the clinical risk-benefit of DME treatment from the patient perspective using the NEI VFQ-25.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Wilmer Eye Institute, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
- Genentech, Inc., South San Francisco, CA, USA.
Zitieren
APA
Bressler, N., Haskova, Z., Kapre, A., & Gentile, B. (2024). Clinically Meaningful Change Estimates for the National Eye Institute Visual Function Questionnaire-25 in Patients With Diabetic Macular Edema. Translational Vision Science & Technology. https://doi.org/10.1167/tvst.13.12.27
Vancouver
Bressler N, Haskova Z, Kapre A, Gentile B. Clinically Meaningful Change Estimates for the National Eye Institute Visual Function Questionnaire-25 in Patients With Diabetic Macular Edema. Translational Vision Science & Technology. 2024. doi:10.1167/tvst.13.12.27
BibTeX
@article{Bressler2024,
author = {Bressler, Neil and Haskova, Zdenka and Kapre, Audrey and Gentile, Brittany},
title = {Clinically Meaningful Change Estimates for the National Eye Institute Visual Function Questionnaire-25 in Patients With Diabetic Macular Edema},
journal = {Translational Vision Science & Technology},
year = {2024},
doi = {10.1167/tvst.13.12.27}
}
EUVIMED